Skip to main content

Table 2 Effects of in vivo treatment with allogeneic mesenchymal stem cells derived from guinea pigs on CD45 immunoreactive leukocytes (pixels × 105) in cross-sections of the colon

From: Allogeneic guinea pig mesenchymal stem cells ameliorate neurological changes in experimental colitis

 

Sham

TNBS

TNBS + gpBM-MSC

TNBS + gpAT-MSC

 

Mucosa

24 h

6.71 ± 1.52

26.09 ± 4.47****

12.97 ± 1.83††

16.22 ± 1.80†*

72 h

6.00 ± 1.82

24.13 ± 2.65****

10.54 ± 1.11††

12.44 ± 1.78††

 

Submucosa

24 h

0.59 ± 0.17

4.38 ± 0.92***

2.02 ± 0.41†

1.56 ± 0.46†

72 h

0.48 ± 0.20

5.69 ± 1.22****

0.82 ± 0.19††††

1.31 ± 0.10†††

 

Muscle

24 h

0.57 ± 0.19

2.07 ± 0.48

1.55 ± 0.38

1.96 ± 0.74

72 h

0.68 ± 0.22

1.91 ± 0.36

0.78 ± 0.39

0.76 ± 0.30

  1. TNBS 2,4,6-trinitrobenzene sulfonic acid, gpBM-MSC guinea pig bone marrow-derived mesenchymal stem cell, gpAT-MSC guinea pig adipose tissue-derived mesenchymal stem cell. †P <0.05, ††P <0.01, †††P <0.001, ††††P <0.0001, significantly different from TNBS; *P <0.05, ***P <0.001, ****P <0.0001, significantly different from sham; n = 4 animals per group per time point